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There are two routes to produce deoxyribonucleoside triphosphates (dNTPs) precursors for 
DNA synthesis, the de novo and the salvage pathways. Deoxyribonucleoside kinases 
(dNKs) perform the initial phosphorylation of deoxyribonucleosides (dNs). Furthermore, 
they can act as activators for several medically important nucleoside analogs (NAs) for 
treatment against cancer or viral infections. Several disorders are characterized by 
mutations in enzymes involved in the nucleotide biosynthesis, such as Lesch-Nyhan disease 
that is linked to hypoxanthine guanine phosphoribosyltransferase (HPRT). 
 
In this thesis, the structures of human thymidine kinase 1 (TK1), a mycoplasmic 
deoxyadenosine kinase (Mm-dAK), and phosphoribosyltransferase domain containing 1 
(PRTFDC1) are presented. Furthermore, a structural investigation of Drosophila 
melanogaster dNK (Dm-dNK) N64D mutant was carried out. The obtained structural 
information reveals the basis for substrate specificity for TKs and the bacterial dAKs. The 
TK1 revealed a structure different from other known dNK structures, containing an α/β 
domain similar to the RecA-F1ATPase family, and a lasso-like domain stabilized by a 
structural zinc. The Mm-dAK structure was similar to its human counterparts, but with 
some alterations in the proximity of the active site. Furthermore several residues important 
for substrate specificity were identified. The crystal structure of PRTFDC1 was structurally 
very similar to its homolog HPRT. PRTFDC1 was classified as having an unknown 
function and with structural and biochemical data we showed that PRTFDC1 has some 
phosphoribosyltransferase activity. A changed behavior of the Dm-dNK N64D mutant was 
previously observed. This mutant displayed an increased sensitivity towards NAs and a 
decreased feedback inhibition. Complexes with substrate and feedback inhibitor provided 
an explanation for the changed behavior of the mutant.  
 
The structural data presented here, provide a foundation for substrate specificity for dNKs. 
The information of differences between human and bacterial enzymes will be of importance 
for the design of new anti-bacterial agents. Mutational studies to improve desired properties 
of an enzyme are an important issue in suicide gene/chemotherapy. Although we have 
found a potential function of PRTFDC1 there are still a lot of questions concerning its 
biological role to answer.    
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 Abbreviations 
Enzymes: 
RNR        ribonucleotide  reductase 
dNK       deoxyribonucleoside  kinases 
TK1       human  thymidine  kinase 
dCK       human  deoxycytidine  kinase 
TK2    human  thymidine  kinase  2 
dGK       human  deoxyguanosine  kinase 
Dm-dNK    Drosophila melanogaster dNK 
Uu-TK     Ureaplasma urealyticum thymidine kinase 
Mm-dAK   Mycoplasma mycoides subsp. mycoides SC deoxyadenosine kinase 
HSV1-TK   Herpes simplex virus type 1 thymidine kinase 
HPRT       hypoxanthine guanine phosphoribosyltransferase 
APRT      adenine  phosphoribosyltransferase 
PRTFDC1   phosphoribosyltransferase domain containing 1 
 
Nucleosides/nucleotides 
dNTP     deoxyribonucleoside  triphophates 
dN      deoxyribonucleoside 
NMP            ribonucleoside monophosphates   
dT        deoxythymidine 
dU        deoxyuridine 
dC        deoxycytidine 
dG        deoxyguanosine 
-MP    monophosphate 
-DP      diphosphate 
-TP      triphosphate 
 
Nucleoside analogs 
NA      nucleoside  analog 
dFdC     2´,2´-difluoro-2´-deoxycytidine 
5FdU       5-fluoro-2´-deoxyuridine 
AZT       3´azido-2´,3´dideoxythymidine 
ddC       2´,3´-dideoxycytidine 
araG       9-β-D-arabinofuranosyl guanine 
GCV     9-(1,3-dihydroxy-2-propoxymethyl)-guanine 
 
 
 
 1. Introduction 
1.1. Production of DNA precursors  
Each of the four deoxyribonucleoside triphosphates (dNTPs) is required for a cell 
to replicate and repair DNA. The constituents building up a deoxyribonucleoside 
(dN) are a purine (adenine or guanine) or pyrimidine base (thymine and cytosine) 
and a deoxyribose (Figure 1). In a cell there are two routes to produce dNTPs, the 
de novo and the salvage pathways.  
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Figure 1. Illustrations of (A) purine, (B) pyrimidine, (C) ribose and (D) deoxyribose.
 
1.1.1. De novo pathway 
In the de novo pathway purine and pyrimidine (d)NTPs are produced. There are 
two separate ways to make purine and pyrimidine nucleotides. Purine nucleoside 
monophosphates (NMPs) are synthesized from several smaller compounds in 
numerous reactions performed by several different enzymes. Regarding 
pyrimidine synthesis, a pyrimidine base is first composed through several 
reactions. The bases are then used to form NMPs. The NMPs are substrates for 
nucleoside monophosphate kinases ((d)NMPKs) that add a second phosphoryl 
group to the NMPs. The formed nucleoside diphosphates (NDPs) are either 
phosphorylated to nucleoside triphosphates (NTPs) by nucleoside diphosphate 
kinases (NDPKs) for RNA synthesis or reduced to deoxyribonucleoside 
diphosphates (dNDPs) by ribonucleotide reductase (RNR) (Thelander & Reichard, 
1979). A third phosphoryl group is then added to form dNTPs, precursors of 
DNA. To produce deoxythymidine monophosphate (dTMP) a different route is 
taken, where deoxyuridine monophosphates (dUMPs) are methylated performed 
by the enzyme thymidylate synthase (Montfort & Weichsel, 1997). 
 
1.1.2. Salvage pathway 
The second route, the salvage pathway recycles nucleobases and dNs from 
nutrients and degraded DNA (Figure 2). The dNs are transported into the cells 
through nucleoside transporter proteins (Plagemann, Wohlhueter & Woffendin, 
1988). The first step in the salvage pathway, which leads towards production of 
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 dNTPs, is to trap the dNs in the cell. This is accomplished by the transfer of a 
phosphoryl group from NTP to a dN by deoxyribonucleoside kinases (dNKs). The 
charge of the dNMP traps the molecule inside the cell and thus transportation out 
of the cell is hindered. Now the deoxyribonucleoside monophosphates (dNMPs) 
can be further phosphorylated to its respective dNTP by (d)NMPKs and NDPKs. 
In addition there is an ongoing recycling of nucleobases catalyzed by enzymes, 
specifically phosphoribosyltransferases (PRTs).  Degraded nucleobases are used to 
form NMPs for either RNA or DNA synthesis (Sinha & Smith, 2001).  
 
 
 
 
 
 
 
 
 
 
 
dN dN
base base
dNMP dNDP dNTP DNA
NMP NDP
RNR (de novo)
(de novo)
dNK (d)NMPK NDPK
PRT (d)NMPK
Figure 2. Simplified scheme of the production of precursors for DNA synthesis, dNTPs.
 
1.2. Deoxyribonucleoside kinases (dNKs)  
dNKs are enzymes catalyzing the first step in the salvage pathway. They perform 
the transfer of a phosphoryl group from a NTP to dN. The dNKs are found in a 
broad range of species in different numbers.  
 
1.2.1. Human dNKs  
There are four different dNKs in a mammalian cell. Two dNKs are situated in the 
cytosol, thymidine kinase 1 (TK1, E.C. number: 2.7.1.21) and deoxycytidine 
kinase (dCK, E.C. number: 2.7.1.74) and two in the mitochondria, thymidine 
kinase 2 (TK2, E.C. number: 2.7.1.21) and deoxyguanosine kinase (dGK, E.C. 
number: 2.7.1.113) (Arnér & Eriksson, 1995; Eriksson et al., 2002). These 
enzymes have complementary substrate specificity and are able to phosphorylate 
all of the natural substrates (Table 1). TK1 has a stricter specificity than the other 
dNKs, and can only phosphorylate deoxythymidine (dT) and deoxyuridine (dU). 
dCK is responsible for the phosphorylation of the remaining substrates in the 
cytosol, deoxycytidine (dC), deoxyadenosine (dA) and deoxyguanosine (dG). In 
the mitochondria there is one pyrimidine specific enzyme, TK2 that can 
phosphorylate dT, dU and dC and a more purine specific, dGK that utilizes dA 
and dG and to some extent dC (Arnér & Eriksson, 1995; Eriksson, et al., 2002). 
Of the human dNKs, TK1 will be discussed in greater detail in paper I.  
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    Location  dT  dU dC dG  dA 
TK1 cytosol  +  +  -  -  - 
dCK cytosol  -  -  + +  + 
TK2 mitochondria  +  + +  -  - 
dGK mitochondria  -  - (+) +  + 
 
 
 
 
 
Table 1. Substrate specificity with natural substrates of the human dNKs. + indicates 
activity, - indicates no activity, (+) indicates some activity, activities are taken from 
(Eriksson, et al., 2002). 
 
1.2.2. Multisubstrate dNK  
Many organisms have been shown to have multiple dNKs with complementary 
substrate specificity. However in insects there is only one dNK with broader 
substrate specificity able to phosphorylate all natural dNs. The first multisubstrate 
dNK to be discovered and cloned was Drosophila melanogaster dNK (Dm-dNK, 
E.C. number: 2.7.1.145) (Johansson et al., 1999; Munch-Petersen et al., 2000; 
Munch-Petersen, Piskur & Søndergaard, 1998). Sequencing of the entire D. 
melanogaster  genome revealed that Dm-dNK indeed was the only existing dNK 
(Adams et al., 2000). At the present time several other insect dNKs have been 
identified, such as Anopheles gambiae and Bombyx mori dNK, that also can utilize 
all dNs (Knecht et al., 2002a; Knecht et al., 2003). Dm-dNK will be discussed in 
greater detail in paper II.      
 
1.2.3. Bacterial dNKs 
The first bacterial dNK to be discovered and characterized was TK from 
Escherichia coli (Okazaki & Kornberg, 1964a; Okazaki & Kornberg, 1964b). 
Recently several TKs from gram positive bacteria have been characterized e.g. 
Ureaplasma urealyticum ( parvum) (Uu-TK) and  Bacillus anthracis ( Ba-TK) 
(Carnrot et al., 2003; Carnrot et al., 2006). Other dNKs to be characterized were 
the deoxyadenosine/deoxycytidine kinase from Bacillus subtilis, which shows 
specificity towards dA and dC (Møllgaard, 1980), and a deoxyguanosine kinase 
(Andersen & Neuhard, 2001). In Lactobacillus acidophilus R-26 two 
heterodimeric kinases were discovered; one dAK-dGK and one dAK-dCK (Ives & 
Ikeda, 1998; Ma et al., 1996). Recently a deoxyadenosine kinase from 
Mycoplasma mycoides subsp. mycoides SC (Mm-dAK) has been characterized 
(Pol & Wang, 2006; Wang et al., 2001) and this enzyme will be described in detail 
in paper III. 
 
1.2.4. Viral TKs 
Herpes simplex virus type 1 TK (HSV1-TK) is a homodimer with a molecular 
weight of ca 80 kDa (Chen & Prusoff, 1978), while Vaccinia virus TK (VV-TK) is 
a tetramer of the same size (Black & Hruby, 1990). These dNKs are referred to as 
viral TKs since they have preferences towards dT (Gentry, 1992). The VV-TK is 
similar to eukaryotic and bacterial TKs but with a shorter C-terminus. HSV1-TK 
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has a broad specificity and can phosphorylate both dT and dC. In addition it has 
thymidylate activity (Chen & Prusoff, 1978; Jamieson & Subak-Sharpe, 1974). 
VV-TK has a narrower substrate specificity that is similar to human TK1 (Solaroli 
et al., 2006b).      
 
1.3. Two families of dNKs 
The first crystal structure of a dNK to be determined was HSV1-TK (Brown et al., 
1995; Wild et al., 1995), and at the present time structural data is readily available. 
Based on the different folds of the dNKs, the structures can be divided into two 
families, a dCK/dGK family (including some viral TKs, such as HSV1-TK) and a 
TK1 family. Nucleotide binding proteins usually possess a phosphate-binding loop 
(P-loop), the only motif shared by the two families. Among the four human dNKs 
the crystal structures of dGK, dCK and TK1 have been determined (Birringer et 
al., 2005; Johansson et al., 2001; Sabini et al., 2003; Welin et al., 2004).  
 
1.3.1. dCK/dGK family 
The dGK and dCK structures are both structurally and sequentially similar. 
Superimposition with the HSV1-TK revealed structural similarity despite low 
sequence identity. Several conserved residues between the structures were 
identified: (i), a glutamine which is hydrogen bonded to the substrate base, (ii), a 
Glu-Tyr couple that is hydrogen bonded to the 3´-hydroxyl group of the 
deoxyribose moiety and (iii), a Glu-Arg couple that is hydrogen bonded to the 
5´OH group of the substrate (Johansson, et al., 2001; Wild, et al., 1995; Wild et 
al., 1997). It was suggested by Wild, et al. (1997) that the glutamic acid in the 
Glu-Arg couple was involved in catalysis. The glutamic acid acts as a base and 
deprotonates the 5´OH of the substrate, allowing the substrate to make a 
nucleophilic attack on the γ-phosphate of the phosphate donor (Wild, et al., 1997) 
(Figure 3). Magnesium is required for this reaction and several arginines in 
proximity help to stabilize the transition state.  A mutational study of the Glu52 in 
Dm-dNK revealed total abolishment of the activity when mutated to a glutamine 
(Egeblad-Welin et al., 2007). The glutamic acid is found in proximity to 5´OH of 
the deoxyribose moiety of all known dNK structures, suggesting a general 
mechanism for all dNKs. The structure of the multisubstrate dNK, Dm-dNK 
revealed a broader dN binding site and thus provides an explanation for the ability 
of Dm-dNK to phosphorylate all four natural substrates (Eriksson, et al., 2002; 
Johansson, et al., 2001). Other recently solved structures belonging to this family 
are the Varicella zoster virus TK (VZV-TK) (Bird et al., 2003) and the first 
bacterial enzyme belonging to this family Mm-dAK (Welin et al., 2007).  
 
1.3.2. TK1 family 
Recent studies have provided significant data concerning the structure of TKs. The 
sequences within the TK1 family are well conserved, and the structures of the 
human TK1, Uu-TK, Clostridium acetobutylicum TK (Ca-TK), VV-TK, Ba-TK 
and a TK from Bacillus cereus showed that they are structurally very similar 
(Birringer, et al., 2005; El Omari et al., 2006; Kosinska et al., 2007; Kuzin et al., 
2004; Welin, et al., 2004). The TK structures revealed a core domain consisting of a six stranded parallel β-sheet sandwiched between several α-helices, and thus 
resemble the ATP binding domain of the RecA-F1ATPase family (Sawaya et al., 
1999). A second domain, with a lasso like loop and a structural zinc was also 
revealed in the TK1 structure (Welin, et al., 2004).  
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Figure 3. General mechanism for dNKs, (the figure has been modified from (Eriksson et 
al., 2002)).  
1.4. Feedback inhibition  
Initial studies showed that several dNKs could be inhibited by their distal end 
product. In the early sixties it was suggested for TK1 that dTTP overlaps both the 
acceptor and the donor site (Ives, Morse & Potter, 1963). The crystal structures of 
Dm-dNK with substrate and feedback inhibitor bound confirmed this type of 
overlapping binding mode (Eriksson, et al., 2002; Mikkelsen et al., 2003). The 
end product of the best substrate for a dNK has been shown to be the most potent 
feedback inhibitor.  
  
1.5. Medical interests 
1.5.1. Nucleoside analogs   
Nucleoside analogs (NA) or pro-drugs are non-toxic until activation through 
phosphorylation by kinases. The NAs are transported into a cell using the same 
transporter system as natural dNs (Plagemann, Wohlhueter & Woffendin, 1988). 
Inside the cell the NAs are phosphorylated, a crucial step for keeping the NA 
inside the cell. This first activation step is carried out by dNKs which 
phosphorylate NAs into a NA-monophosphate (NAMP). The NAMPs are then 
phosphorylated in two steps to NA-triphosphate by NMPK and NDPK (Van 
Rompay, Johansson & Karlsson, 2000). The activated form of an NA can act as a 
terminator of DNA elongation, interfere with reverse transcriptase or cellular 
DNA polymerases, and induce apoptosis (Klopfer et al., 2004; Macchi & Mastino, 
2002). Furthermore, some NAs can inhibit other enzymes in the nucleotide 
biosynthesis pathway simultaneously, like 2´,2´-difluoro-2´-deoxycytidine (dFdC) 
inactivates RNR in its diphosphate form (Ostruszka & Shewach, 2003). TK1 
phosphorylates 5-fluoro-2´-deoxyuridine (5FdU) to its active form, 5FdU-
monophosphate, which inhibits thymidylate synthase (Santi & McHenry, 1972).  
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1.5.2. Suicide gene/chemotherapy 
The basic idea of suicide gene/chemotherapy is to transfer a gene that can activate 
a specific NA into cancer cells, hence killing the cancer cells by administration of 
NAs (Niculescu-Duvaz & Springer, 2005). This is accomplished through first 
delivering the gene of interest, which encodes the enzyme, into the cancer cells via 
a vector, e.g. adenoviruses. Subsequent expression of the gene inside the cancer 
cells followed by the administration of the NA ultimately kills the cancer cells. 
This has been implemented using HSV1-TK and 9-(1,3-dihydroxy-2-
propoxymethyl)-guanine (GCV), an NA not phosphorylated by the human dNKs 
(Moolten, 1986). By the bystander effect neighboring cells are killed by the 
transfer of the activated NAs by cell-cell contacts (Mesnil & Yamasaki, 2000). By 
fusing the genes of HSV1-TK and guanosine monophosphate kinase (GMPK) a 
lower IC50 was observed compared to the HSV1-TK alone (Willmon, Krabbenhoft 
& Black, 2006). A clinical trial using HSV1-TK gene in a nonreplicative 
adenoviral vector in combination with GCV, towards malignant mesothelioma 
increased the survival time for some patients (Sterman et al., 2005).  
 
1.6. Purine phosphoribosyltransferases  
Purine phosphoribosyltransferases are salvage enzymes recycling purine 
nucleobases hypoxanthine (Hx), guanine (G) and adenine (A) to form the 
respective NMPs using α-D-5-phosphoribosyl 1-pyrophosphate (PRPP) and Mg
2+ 
in a reversible reaction (Figure 4). In human cells there are two well described 
enzymes carrying out these reactions, hypoxanthine guanine 
phosphoribosyltransferase (HPRT, E.C. number: 2.4.2.8) and adenine 
phosphoribosyltransferase (APRT, E.C. number: 2.4.2.7). The HPRT has been 
intensively studied for mainly two reasons. First, most protozoan parasites lack the 
de novo pathway of purine nucleotides and have to depend on their salvage 
enzymes. Parasitic HPRTs have thereby become a potential target for the 
development of anti-parasitic drugs (Wang, 1984). Second, mutations in human 
HPRT and Lesch-Nyhan syndrome are linked, as described below. HPRT and its 
homolog phosphoribosyltransferase domain containing 1 (PRTFDC1) will be 
discussed in more detail in paper IV.  
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1.7. Disorders  
Several disorders are characterized by mutations or lack of enzymes in the 
nucleotide biosynthesis process. Mitochondrial DNA depletion syndrome (MDS) 
is characterized by a quantitative defect of mitochondrial DNA (Moraes et al., 
1991). Mutations in dGK and TK2 have been linked to MDS, resulting in 
symptoms such as myopathy and liver failure (Mandel et al., 2001; Moraes, et al., 
1991; Saada et al., 2001). Mutations in the HPRT gene that lead to an almost 
inactive enzyme, giving rise to a disorder called Lesch-Nyhan disease. Patients 
having the disorder display symptoms such as retarded motor development and 
self injurious behavior (Nyhan, 2005). This disease was first described by Michael 
Lesch and William Nyhan in 1964 (Lesch & Nyhan, 1964). Some mutations in 
HPRT lead to partial activity of the enzyme and can cause gout arthritis (Jinnah et 
al., 2000). 
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2.1. Human thymidine kinase 1, TK1 (Paper I) 
2.2. Aim of study 
At the time, though several crystal structures of enzymes belonging to the 
dCK/dGK family have been determined, the structure of a TK1 family enzyme had 
not been solved, despite its biological importance and its role as an activator of 
several pro-drugs. Low sequence identity indicated a structure different from the 
dCK/dGK family. Our aim was to determine TK structures of both human and 
mycoplasmic origin, and to study potential differences for the design of new anti-
microbial agents targeting the bacterial TKs. A further aim of our study was to 
examine the human TK1 acceptor site and determine how it might be exploited for 
the development of new pro-drugs.  
 
2.3. Background 
More than twenty years ago the first eukaryotic TK gene, the human TK, was 
cloned and subsequently studied (Bradshaw, 1983; Bradshaw & Deininger, 1984). 
The gene coding for TK1 is located on chromosome 17 (McDougall, Kucherlapati 
& Ruddle, 1973; Miller et al., 1971). The human TK1 is a cytosolic enzyme 
consisting of 234 amino acids and a subunit weight of 24 kDa (Bradshaw & 
Deininger, 1984; Sherley & Kelly, 1988a). The first published TK1 sequence 
contained a Met in position 106 though Berenstein, et al. (2000) later showed that 
the correct residue at this position should be a Val (Berenstein et al., 2000; 
Bradshaw & Deininger, 1984).  
 
TK1 is a cell-cycle regulated enzyme found in dividing cells. The levels of the 
TK1 enzyme start to increase in late G1 cells, having their peak in the S phase and 
then disappearing during mitosis (Bello, 1974; Sherley & Kelly, 1988b). While 
deletion of forty amino acids of the C-terminus of TK1 totally diminishes the cell 
cycle regulation but retains activity of TK1, deleting only ten residues of the 
carboxyl terminus does not affect the cell cycle regulation. This suggests that 
amino acids within the thirty residues of the C-terminus are involved in regulating 
the cell cycle (Kauffman & Kelly, 1991). Later work revealed that a sequence 
containing three residues, Lys, Glu and Asn (KEN)  was identified in Cdc20, 
which is a substrate for degradation by the Cdh1-APC complex (Pfleger & 
Kirschner, 2000). The same KEN sequence was found in the C-terminus of TK1 
and mutational studies of this sequence confirmed its necessity for degradation by 
the APC/C-Cdh1-mediated proteolysis (Ke & Chang, 2004). It has been 
demonstrated that TK1 gets greatly phosphorylated during the G2 and M phase 
and shows a decreased affinity towards dT prior to degradation (Chang, Huang & 
Chi, 1998; Ke et al., 2003). Dietary zinc deficits lead to lower TK activity in rat 
and sheep fetuses. These findings led to the idea that TK1 was a Zn
2+ dependent 
enzyme (Dreosti & Hurley, 1975; Duncan & Hurley, 1978), but this was not 
confirmed until the first structures of TKs were solved (Welin, et al., 2004). 
Concerning quaternary structure, both dimeric and tetrameric forms of TK1 have   17 
 
 
been observed and are dependent on the presence of ATP. In the absence of ATP 
TK1 displays a lower affinity towards dT while when incubated with ATP an 
enzyme with higher affinity for dT is observed (Munch-Petersen, Tyrsted & 
Cloos, 1993). A recent investigation showed that the wild type TK1 behaved as a 
tetramer whereas the N and C-termini truncated TK1 behaved as a dimer, 
independent of incubation with dT and ATP (Birringer et al., 2006). 
 
2.3.1. Substrate specificity 
TKs have the most narrow substrate specificity among the dNKs and are only able 
to phosphorylate dT and dU among the natural substrates (Munch-Petersen et al., 
1991). Early studies showed that halogen substitutions at the C5 position of 
thymine were good substrates for Ec-TK, as well as for TK1 (Eriksson et al., 
1991; Okazaki & Kornberg, 1964a). TK1 can activate several important pro-drugs 
for medical use, e.g. the anti HIV drug, 3´azido-2´,3´dideoxythymidine (AZT) and 
the anti cancer agent, 5FdU (Eriksson, et al., 1991; Furman et al., 1986). Large 
modifications at the N3 position also work to some extent as phosphate acceptors 
(Al-Madhoun et al., 2002; Lunato et al., 1999). In summary, modifications at the 
N3 and C5 positions of the base and at the 3´ position are effective substitution 
sites. 
 
2.3.2. Medical interests 
Since TK1 is expressed in proliferating cells it can be used as a marker in clinical 
medicine (Gronowitz et al., 1984). Cancer cells rapidly divide making TK1 a 
marker for different cancer diseases (Li et al., 2005; Zhang et al., 2006). 
Antibodies that target the C-terminus of TK1 have been designed and may serve 
as a good diagnostic marker in the detection of abnormal amounts of TK1 in 
serum (He et al., 1996; He et al., 2000) TK1 can act as an activator of several 
important NAs, which makes it a target for the design of new NAs or the redesign 
of old ones. To develop inhibitors targeting bacterial TKs but not the human TK1 
would be of interest, especially for bacteria developing multi resistance towards 
antibiotics.  
 
2.4. Solving the TK1 structure using SIRAS 
2.4.1. Crystallization 
The TK1 used for crystallization was a truncated version of the protein lacking the 
last 41 amino acids. To stabilize the protein during the crystallization process it 
was co-crystallized with its feedback inhibitor, dTTP. Earlier work showed that 
dTTP stabilizes Dm-dNK for crystallization (Mikkelsen, et al., 2003). Crystals 
were obtained with hanging drops using the vapor diffusion method. Protein 
crystals grew typically in 6-12 hours as plates and rods to a size of 80x60x60 μm
3 
and 220x60x60 μm
3 respectively. A native data set to 2.4 Å resolution was 
collected at the ESRF. 
 
2.4.2. Heavy atom soaking 
Since no similar structures were available at the time, other methods than molecular replacement had to be considered. To solve the structure, several heavy 
atoms were soaked into the crystals. By varying the concentrations and the 
soaking times of the heavy atom solutions a successful combination, 10 mM 
KAu(CN)2 for 40 min, was found. To remove unspecific bound heavy atoms, 30 s 
of back-soaking were carried out. A full data set (gold data) was collected at the 
peak (λ = 1.04 Å). The native data collected and the gold data were non-
isomorphous and thus the structure could not be solved. We also collected a data 
set where the crystal had been soaked in 10 mM lead acetate for 40 min. This data 
set turned out to be isomorphous to the gold data and could be used for structure 
determination.  
 
2.4.3. Structure determination 
Single isomorphous replacement with anomalous scattering (SIRAS) was applied 
for structure determination. Using SHELXC/D (Bricogne, 1997; Schneider & 
Sheldrick, 2002) twelve heavy atom sites could be located. During refinement of 
these heavy atom sites two new sites were added, so a total of fourteen sites were 
used in AutoSHARP (Bricogne, 1997; Bricogne et al., 2003). Initial maps were 
greatly improved with averaging using eight fold non-crystallographic symmetry 
(NCS) in DM, CCP4 (CCP4, 1994). To match the amino acid sequence into the 
electron density, the known motif, the P-loop was used. Earlier studies had shown 
that the feedback inhibitor was bound to the P-loop (Mikkelsen, et al., 2003), and 
a larger electron density blob was identified as the phosphates bound to this motif 
(Figure 5A). Most of the structure was built in this map using O (Jones et al., 
1991). The structure was then built and refined using native 2.4 Å resolution data. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
Figure 5. (A) Initial electron density map of the P-loop contoured at 1σ. (B)  Tetramer with 
four zinc sites and two gold sites illustrated by an anomalous Fourier map contoured at 5σ. 
All figures containing protein structure have been made using Pymol (DeLano, W.L. The 
PyMOL Molecular Graphics System (2002) DeLano Scientific, Palo Alto, CA, USA.).
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2.4.4. Heavy atom sites 
The heavy atom sites used to solve the structure were localized using anomalous 
Fourier maps with CCP4 (CCP4, 1994) . Eight stronger and six weaker sites were 
used in the structure determination and the eight stronger sites corresponded to 
eight zinc atoms bound to each subunit in the two tetramers. In addition, six 
weaker gold sites were found to be bound to Cys79 in six of the eight subunits 
(Figure 5B). The isomorphous and anomalous differences from the six gold sites 
and the anomalous signal from the eight zinc sites were sufficient to solve the 
structure. It was later shown that the human TK1 structure could be solved using 
zinc ion anomalous diffraction (Birringer, et al., 2005).  
 
2.5. Structure of the human TK1  
The TK1 structure revealed a fold different from the earlier known structures of 
the dNK family. The structure is built up from an α/β and a lasso like domain 
containing a zinc. The α/β domain in TK1 has a central β-sheet consisting of six 
parallel strands surrounded by five α-helices (Figure 6A). The DALI server (Holm 
& Sander, 1995) revealed that the α/β domain of the structure had a high 
similarity to enzymes belonging to the RecA-F1ATPase family (Sawaya, et al., 
1999). The active site is buried between the two domains. All structures solved in 
this TK1 family have been shown to be very similar. The N-terminus is flexible 
and starts to become ordered at Arg18, while there are only a couple of residues 
missing in the C-terminus for the truncated enzyme. The structure of the wild type 
enzyme did not reveal more of the C-terminus indicating flexibility (unpublished 
data). The structures of the human TK1 and Uu-TK were simultaneously solved, 
with both structures showing a high structural similarity with a root mean square 
deviation (RMSD) of 1.32 Å for 152 Cα-atoms. 
 
2.5.1. Quaternary structure   
The eight subunits in the crystal structure form two tetramers. The tetramer 
contains a central channel with mainly polar and charged residues in the interface 
(Figure 6D). The subunits in the tetramer have 222 symmetry. There are two types 
of dimer interactions in the tetramer. A helical interaction between α1 in subunit A 
and α1 in subunit B (Figure 6B), is strikingly similar to the dimerization of CobA 
(RMSD of 1.95 Å over 103 aligned residues), which has the most similar α/β 
domain structure to TK1 according to the DALI server (Holm & Sander, 1995). 
CobA catalyzes the transfer of an adenosyl moiety to corrinoid substrates (Bauer 
et al., 2001). The second dimer interaction is connected via a range of water 
molecules in between two anti-parallel β-sheets in subunit A-C (Figure 6C).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. (A) Monomeric structure of 
TK1. (B) Helical dimer interaction 
between subunit A-B. (C) Dimer 
interaction between subunit A-C. (D) 
Tetrameric structure of TK1. In all 
structures dTTP is shown with sticks 
and magnesium and zinc with spheres, 
yellow and gray respectively. 
A B
C
D
Lasso
α/β
 
 
2.5.2. Lasso domain 
Unique for the TK1 family is a domain referred to as the “lasso domain”. This 
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 domain has a repeated CXXC motif similar to other structural zinc motifs, where 
four cysteine are coordinating a zinc atom (Vallee & Auld, 1990). In some species 
the last cysteine in this motif is replaced by a histidine. The zinc has a structural 
role and is located far from the active site. The lasso domain consists of roughly 
forty amino acids and between the strands in the β-ribbon the lasso opens up and 
residues 167-179 form a long loop that covers one side of the dN site. This loop is 
stabilized by hydrogen bonds from main chain atoms of the tip of the loop, by a 
conserved Arg-Tyr couple (Figure 7), and from interactions of the dN bound to the 
enzyme. The crystal structure of Ca-TK with an empty acceptor site and an ADP 
bound to the donor site verify the flexibility of the loop since part of the loop is 
missing (Kuzin, et al., 2004). The combination of an α/β domain with a zinc 
containing lid has been observed in bacterial adenylate kinases, where the zinc 
connects the tip of the lid in the adenylate kinase (Berry & Phillips, 1998; Glaser 
et al., 1992). The role of the zinc is completely different in TK1, however, since 
the zinc binds at the base of the β-ribbon of the lid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
V174
V172
E171
E169
Y181
R165
C153
C156
C185
C188
Figure 7. Lasso domain of the TK1 structure. Residues involved in binding of the zinc 
and stabilization of the loop are shown and numbered.   
2.5.3. Acceptor site 
When a substrate is bound to the enzyme the lasso loop closes down over the base 
of the substrate. All the hydrogen bonding interactions between the thymine base 
and enzyme are via main chain atoms coming from both the lasso and the α/β 
domain. The feedback inhibitor dTTP binds with the dT part in the acceptor site 
and the triphosphates to the P-loop in a manner similar to earlier observations 
concerning bound feedback inhibitors (Johansson, et al., 2001; Mikkelsen, et al., 
2003). Glu98 was in proximity to the 5´oxygen of the dT moiety of the dTTP and 
is believed to be the catalytic base and thus may have the same mechanism as in 
other dNKs (Eriksson, et al., 2002; Wild, et al., 1997). This glutamic acid was 
also shown to move towards the 5´OH when only thymidine was bound in Uu-TK 
(Kosinska et al., 2005). The 3´OH of the deoxyribose of dTTP is anchored via 
hydrogen bonds from two conserved residues, Asp58 from the α/β domain and 
  21 
 
 Gly176 from the lasso domain (Figure 8). The rather small dN binding site and the 
main chain interactions with the substrate base explains the narrow substrate 
specificity for TKs. The feedback inhibitors have been shown to bind tightly to the 
enzymes allowing TK1 to acquire a dTTP molecule during the purification 
procedure (Birringer, et al., 2005; Birringer, et al., 2006). This has also been 
observed for the human TK2 where several end products (dTTP, dCTP and dATP) 
were found to be bound to the purified enzyme (Barroso, Elholm & Flatmark, 
2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F128
V172
V174 G176
D58
R60
P-loop
Figure 8. Phosphate acceptor site of TK1 with bound dTTP. Residues involved in binding 
the dN moiety are shown and numbered. The volume of the dN binding site is illustrated 
with a surface.   
 
2.5.4. Comparison with other dNKs 
Enzymes belonging to the TK1 family have a conserved P-loop which is the only 
conserved motif between the dCK/dGK and TK1 family. By superimposing the P-
loop, the subsequent α1 superimpose closely on the corresponding α1 of other 
dNKs. The other helices do not superimpose and other dNKs have more helices, 
which are located differently and are longer. In particular, the substrate binding 
site is formed by two helix-pairs in dNKs and the lid that closes over the 
phosphate binding site of the phosphate donor is a helical structure in dNKs.  
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2.5. TK1 and drug design 
In this study the structures of two TKs of human and mycoplasmic origin were 
solved. The nearly identical active sites in the enzymes complicate the possible 
design of anti-mycoplasmic agents targeting only the Uu-TK enzyme. In the active 
site there is only a Thr to Ser substitution in the Uu-TK. The human TK1 has been 
shown to accept modifications at the 3´OH position such as AZT. In addition, 
boronated compounds with N3 substitutions of the thymine base are 
phosphorylated by TK1. The N3 position points towards the interface between the 
α/β and the lasso domain and a partly closed lasso domain could be a reason for 
accepting these substrates.  
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3. Drosophila melanogaster deoxyribonucleoside 
kinase, Dm-dNK (Paper II) 
3.1. Aim of study 
In a random mutagenesis investigation of Dm-dNK a double mutant, N45D/N64D, 
revealed increased sensitivity toward several NAs when the gene was transformed 
into a TK deficient E. coli strain. Furthermore, decreased inhibition with the end 
product dTTP was observed (Knecht, Munch-Petersen & Piskur, 2000). 
Interestingly, both these mutations were located far from the active site and this 
finding initiated further investigations. Structural and biochemical 
characterizations were carried out for the separate mutations (N45D and N64D) to 
reveal the basis for the obtained behavior of the double mutant.    
 
3.2. Background 
Dm-dNK differs from other dNKs since it is capable of phosphorylating all natural 
substrates for DNA synthesis, but with higher substrate specificity towards 
pyrimidines.  Dm-dNK has shown higher catalytic rates both with natural 
substrates and nucleoside analogs compared to human dNKs and HSV1-TK 
(Johansson, et al., 1999; Munch-Petersen, Piskur & Søndergaard, 1998). 
Truncating the last twenty residues of Dm-dNK revealed similar Km values but a 
higher turn over number than the wild type enzyme (Munch-Petersen, et al., 
2000). For both the crystal structure and gel filtration experiments of Dm-dNK, a 
homodimeric protein has been observed (Johansson, et al., 2001; Knecht, et al., 
2002a). Although Dm-dNK can phosphorylate dT, dC, dG and dA, its only potent 
feedback inhibitor is dTTP (Knecht, Munch-Petersen & Piskur, 2000; Knecht, et 
al., 2002a).  
 
3.3. Mutational studies  
To improve phosphorylation of nucleoside analogs, Dm-dNK has been thoroughly 
investigated and several mutational studies have been carried out. Knecht, et al. 
(2002b) identified three active site residues using the crystal structure of dGK to 
be the basis for a more purine specific enzyme. The corresponding residues 
(V84A, M88R and A110D) in Dm-dNK were mutated and the triple mutant turned 
out to be more purine specific than the wild type Dm-dNK (Knecht et al., 2002b). 
Recently it was demonstrated that the M88R mutant also showed increased 
sensitivity towards the purine analog, 9-β-D-arabinofuranosyl guanine (araG) 
(Solaroli et al., 2006a). Several mutants increasing the sensitivity toward 
nucleoside analogs were identified using high-frequency random mutagenesis. 
Especially one double mutant, N45D/N64D, displayed a decreased lethal dose 
(LD)100 towards several nucleoside analogs when the gene was transformed into a 
TK deficient E. coli strain (Knecht, Munch-Petersen & Piskur, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N45
D64 ~10Å
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D64 E171 E172
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LID LID
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Figure 9. (A) Structure of Dm-dNK N64D with bound dTTP and positions N45 and D64 
in sticks and colored red. (B) Structure-based sequence alignment for the regions 
surrounding the mutations for Dm-dNK (accession number: Q9X7T6), dGK (accession 
number: Q16854), dCK (accession number: P27707) and TK2 (accession number: 
O00142). (C) and (D) 2Fo-Fc electron density map contoured at 1σ  for residues D64, 
E171, and E172 in blue. Fo-Fc electron density map contoured at 3σ (before the ligands 
were included in the refinement) for dTTP and dT and a sulfate ion in green.   
3.3.1. Effects of N45D/N64D 
An increase in sensitivity towards AZT and 2´,3´-dideoxycytidine (ddC) of 316-
fold and 11-fold, respectively, in LD100 values for the N45D/N64D mutant were 
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shown in a TK deficient strain (Knecht, Munch-Petersen & Piskur, 2000). 
Although both mutations were located far from the active site ~30Å for N45D and 
~10Å for the N64D (Figure 9A), an impact on the sensitivity towards nucleoside 
analogs was observed. Another characteristic observed with the double mutant 
was decreased feedback inhibition by dTTP and lower activity concerning natural 
substrates (Knecht, Munch-Petersen & Piskur, 2000).  
 
3.4. N64D mutant 
3.4.1. Effects of the N64D mutant 
Asn45 is a non-conserved residue while Asn64 is conserved among dNKs (Figure 
9B). To reveal the significance of the two point mutations they were investigated 
separately. The mutation responsible for the changed behavior of the Dm-dNK 
turned out to be the N64D, which alone showed similar patterns as the double 
mutant. The N64D mutant required the highest concentration of dT for growth in a 
TK deficient E. coli strain followed by N45D/N64D and N45D. The N64D mutant 
showed a 300-fold decrease in LD100 towards AZT, similar to the double mutant. 
The same pattern was observed concerning the feedback inhibition with dTTP. 
N45D behaved as the Dm-dNK while in the N64D mutant the inhibition was 
almost abolished. To investigate the observed changes, the Dm-dNK N64D mutant 
was co-crystallized together with the substrate, dT, and the feedback inhibitor, 
dTTP. 
 
3.4.2. Structural basis for the changed behavior of the N64D mutant  
The crystal structure of the N64D-dTTP complex did not display any differences 
compared to the wild type structure. Surprisingly there was still a hydrogen bond 
interaction between Asp64 and Glu171 despite the negative charges (Figure 9C). 
The LID is kept in place by several interactions with the phosphates of the dTTP 
molecule. The unfavorable interaction between an aspartic acid and a glutamic 
acid has been observed in several cases (Flocco & Mowbray, 1995). The 
decreased feedback inhibition by dTTP can probably be explained by the energetic 
cost holding these two carboxylates together. In the crystal structure of N64D-dT 
complex the situation is different. When the LID is not held in place with the 
strong interactions with the phosphates the two carboxylates repel and destabilize 
this part of the structure (Figure 9D). The unordered LID structure leads to the 
loss of a hydrogen bond between Glu172 and the 3´OH group of the deoxyribose. 
The loss of this bond creates a more open dN acceptor site and more room for the 
bulkier AZT molecule, which are displayed by the increased sensitivity towards 
AZT. This would also explain the increased K0.5 with the natural substrates (dT, 
dC, dA and dG).  
 
 
 
 
 
 
   27 
 
 
 
 
 
3.5. Medical/industrial use 
Modifying  Dm-dNK to obtain an enzyme more specific towards nucleoside 
analogs and less sensitive for feedback inhibition could be a potential candidate as 
a suicide gene in combined gene/chemotherapy, in the same fashion as HSV1-TK. 
Another use of Dm-dNK could be for large-scale production of dNTPs or 
phosphorylated analogs (Munch-Petersen, et al., 2000).       
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4. Mycoplasma mycoides deoxyadenosine kinase, 
Mm-dAK (Paper III) 
4.1. Aim of study 
A significant amount of structural information concerning dNKs has been 
obtained in the last decade, but no structure of a bacterial enzyme belonging to the 
dCK/dGK family has been solved. Mm-dAK was characterized in an earlier study 
and crystallographic studies were then initiated to explore differences between the 
bacterial enzyme and its human counterparts. Additionally, activity measurements 
of several NAs were performed to identify potential leads for future drug design.     
 
4.2. Background 
Bacterial dNKs vary in number, and in mycoplasmas there are two different 
enzymes, a TK and a dAK. Among mycoplasmic TKs, Uu-TK has been 
characterized and its structure has been determined (Carnrot, et al., 2003; 
Kosinska, et al., 2005; Welin, et al., 2004). The most studied enzyme belonging to 
the dCK/dGK family in mycoplasmas is Mm-dAK. This was the first bacterial 
dNK belonging to this family to have its crystal structure determined.  
 
Mycoplasmas are the smallest self replicating organisms and are further 
characterized by a lack of a cell wall and a low G+C content. This group of 
organisms can cause disease in animals, plants, and insects (Razin, Yogev & Naot, 
1998). They can infect a broad range of hosts, where Mm infects cattle and buffalo 
and can cause a respiratory disease called contagious bovine 
pleuropneumonia(Pilo, Frey & Vilei, 2006). Human pathogens such as Uu and 
Mycoplasma pneumoniae (Mp) can cause urinary tract infections and pneumonia 
(Hammerschlag, 2001; Pollack, 2001). Mycoplasmas are unable to produce purine 
and pyrimidine bases de novo and are thus dependent on the salvage enzymes for 
production of NTP/dNTPs (Pollack, Williams & McElhaney, 1997). In Uu  no 
genes for RNR were found and no genes for nucleotide diphosphate kinase have 
been discovered in mycoplasmas in general (Glass et al., 2000). The Mm-dAK is 
capable of phosphorylating, in order of catalytic efficiency, dA, dG, and dC. In 
addition several important nucleoside analogs can be phosphorylated while 
ribonucleosides are barely phosphorylated at all. 
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4.3. Structure of Mm-dAK 
The sequences of Mm-dAK and dCK are ~25% identical, indicating that they have 
similar structures. Initial attempts to solve the structure of Mm-dAK with 
molecular replacement failed, so purification of selenomethionine (SeMet) 
substituted protein was initiated. Several SAD data sets of SeMet-crystals were 
collected without any success. At the time these experiments were taking place 
new molecular replacement trials with a new version of Phaser (McCoy et al., 
2005) were carried out and a correct solution was found. The Mm-dAK structure 
was solved and the structure revealed high structural similarity with dCK, dGK 
and Dm-dNK. The structure of Mm-dAK revealed a five stranded parallel β-sheet 
surrounded by eight α-helices (Figure 10A). Mm-dAK is a dimer like other 
enzymes belonging to the dCK/dGK family.  
 
4.3.1. Mm-dAK complexes 
Three different complexes of Mm-dAK were determined, with the feedback 
inhibitors dATP and dCTP, and the products dCMP + dCDP. The overall structure 
between the complexes is relatively unchanged except in a few regions. A tyrosine 
moves ~ 8Å in the pyrimidine complexes compared to the dATP complex to make 
hydrophobic interactions with an α-helix of the C-terminus from a symmetry 
related molecule. The Mm-dAK-dATP complex was crystallized in space group 
C2 with six molecules in the asymmetric unit, while the pyrimidine complexes 
were crystallized in P31 with a dimer in the asymmetric unit. In all complexes 
hexamers of three dimers can be generated. The arrangements of the dimers, 
however, are different and are believed to be crystal artifacts. This also coincides 
with Mm-dAK eluted as a dimer during gel filtration chromatography. This is in 
agreement with other known dimeric structures of the dCK/dGK family.  
 
4.3.2. Mm-dAK-dATP  
The dATP molecule was known from kinetic data to be a potent inhibitor of Mm-
dAK and was therefore used in crystallization trials. The dATP molecule binds in 
a reverse mode with its dN moiety in the acceptor site and the phosphates 
occupying the P-loop. The adenine base makes stacking interactions with Met57 
and Phe86, where the methionine corresponds to a phenylalanine in dGK and 
dCK. The conserved Gln54 that interacts with the tip of the base is in most 
subunits hydrogen bonded to N6 position of the adenine (Figure 10B). Tyr42 is 
stacked against the C2 position of the base. The Mg
2+ observed was bound in 
proximity to Glu150 which corresponds to the opposite side compared to earlier 
observations in TK1 and Dm-dNK (Mikkelsen, et al., 2003; Welin, et al., 2004).  
 
 
 
 
 
  
 
Figure 10. (A), Monomer of the dimeric Mm-dAK structure in complex with dCTP, 
illustrating the location of the conserved P-loop and LID motif. Comparison of feedback 
inhibitor complexes (B) dATP and (C) dCTP, volume of the dN binding sites are illustrated 
by surfaces. (D) Comparison of the LID region, Mm-dAK-dCTP, Mm-dAK-dATP and 
Mm-dAK-dCMP-dCDP are shown in red, black and blue respectively. Magnesium ions 
are shown in spheres and have the same color as the complex (E) Superimposition of 
several other similar protein structures color coded in Table 2.
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4.3.3. Mm-dAK-dCTP   
Kinetic studies using dCTP revealed that this nucleotide works as a phosphate 
donor. So the binding of dCTP as a feedback inhibitor was not expected. The 
dCTP binds in a similar fashion as the dATP molecule, though there are some 
small side chain alterations in the acceptor site. The conserved glutamic acid has 
moved closer into the dN substrate binding pocket and interacts with the N3 and 
N4 position of the cytosine. Tyr42 is now hydrogen bonded to the 2-oxo of the 
cytosine (Figure 10C). No Mg
2+ was observed in this complex.  
 
4.3.4. Mm-dAK-dCMP-dCDP 
Since dCTP could work as a phosphate donor, crystallization trials using both dC 
and dCTP were performed. The electron density from this complex was 
interpreted as two products, dCMP and dCDP bound to the active site. The 
deoxycytidine part of dCMP binds like the dN moiety of dCTP, while the dCDP 
binds to the P-loop. The deoxycytidine part of the dCDP is very flexible and only 
the diphosphate is visible in the density. Weak density for a Mg
2+ was seen in this 
complex as well, but bound to the opposite side compared to the Mm-dAK-dATP 
complex. In this complex the Mg
2+ is bound in proximity to Glu77. 
 
4.3.5. LID region     
The LID region with the conserved motif [RXXXRXRXXE] is present in all 
dCK/dGK family enzymes. When the P-loop is occupied by a triphosphate the 
conserved arginines are usually positioned towards the negatively charged 
phosphates. This binding mode has been observed in Dm-dNK in complex with 
dTTP and in dGK in complex with dATP
1 (Johansson, et al., 2001; Mikkelsen, et 
al., 2003). In Mm-dAK the LID region takes different conformations in the 
different complexes. The Arg141 in the LID motif is positioned in the same 
conformation in all three complexes as well as Glu150. This glutamic acid is 
interacting with the 3´OH of the deoxyribose moiety. Residues 145-147 are more 
flexible but the rest of the LID is positioned in the same orientation. For the Mm-
dAK-dCTP complex the main chain of the LID is located 4-5 Å further away from 
the phosphates compared with other Mm-dAK complexes (Figure 10D). A 
possible explanation for this is the unusual position for the bound magnesium, 
which might push the arginines away from the phosphates.  
 
 
 
 
 
 
 
 
1 Originally the structure of dGK was described in complex with ATP. After later 
evidence the ligand has been reinterpreted as a dATP.  
Organism PDB-
code 
RMSD 
(Å) 
Aligned 
residues 
Color 
M.mycoides  2JAQ -  -  Red 
D.melanogaster  1OE0 1,46  156  Orange 
H.sapiens  1P61 1,75  172  Magenta 
H.sapiens  2OCP 1,75  175  Brown 
Varicella Zooster Virus  1OSN  2,05  147  Cyan 
S.cerevisiae  3TMK 2,2  151  Blue 
HSV1 1P7C  2,2  169  Yellow 
B.stearothermophilus  1ZIN 2,4  137  Green 
 
Table 2. Structural comparison of Mm-dAK with similar structures, superimposition is 
shown in Figure 10E. TMPK – thymidylate kinase, AMPK – adenylate kinase.  
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Figure 11 (previous page). Amino acid sequence alignment of M. mycoides (Mm, accession 
no: Q93IG4), M. pneumoniae M129 (Mp, accession no: P75396), M. genitalium G37 (Mg, 
accession no: P47510), U. urealyticum (Uu, accession no: Q9PR59), human 
deoxyguanosine kinase (dGK, accession no: Q16854) and deoxycytidine kinase (dCK, 
accession no: P27707). The P-loop and LID region and amino acids in proximity of the 
acceptor site with numbering from Mm-dAK are marked. Residues that differ and residues 
that are conserved with Mm-dAK numbering are shown above and below the alignment 
respectively. Black and white boxes refer to identical and similar residues respectively. The 
sequence alignment was made using ClustalW (Chenna et al., 2003) and ESPript (Gouet et 
al., 1999).   
 
4.3.6. Comparison with other dNKs and (d)NMPKs 
The high sequence similarity between dCK, dGK and Dm-dNK indicated that the 
structures of these enzymes would be similar. Superimposition of these enzymes 
to the Mm-dAK structure showed an RMSD of ~1.5-1.8 Å. Several (d)NMPKs 
and viral TKs were identified as similar structures using the DALI server (Holm & 
Sander, 1995). All structures displayed in table 2 were superimposed and clearly 
illustrates the similarity of the core structures (Figure 10E). 
 
 
4.3.7. Mycoplasmic enzymes belonging to the dCK/dGK family  
When sequences from human pathogenic mycoplasmas are compared they reveal a 
sequence identity of ~22-25%. Most of the residues in the active site proximity are 
conserved compared to its human counterparts with three exceptions: (i), Tyr42; 
(ii) Met57; and (iii) Asn90 (Figure 11). (i), a tyrosine in this position is not 
observed in other mycoplasma species or in the human counterparts. (ii), Met57 
varies among the different sequences: it is a phenylalanine in the other 
mycoplasmas, a serine in dGK and an alanine in dCK. The residue in this position 
is of key importance for substrate specificity of the enzyme. Enzymes having a 
hydrophobic amino acid in this position, like Mm-dAK and dCK, show broader 
substrate specificity. Both of these enzymes have higher activity (kcat/Km) towards 
dA, dG and dC, although dGK can phosphorylate dC to some extent (Eriksson, et 
al., 2002). The cause for the specificity is a conserved aspartic acid that interacts 
with the N6 position of adenine and N4 of cytosine. In dGK a serine is hydrogen 
bonded to the aspartic acid, hence this amino acid is not free to adopt different 
conformations depending on the substrate. In Mm-dAK and dCK this aspartic acid 
is not locked in one position and can adopt different conformations depending on 
the substrate. (iii), Asn90 is conserved among the mycoplasmic sequences shown, 
while it is a leucine in dGK and dCK. The asparagine in Mm-dAK interacts with 
the Tyr42 and is situated 5.5 Å from the edge of the base.  
 
4.4. Mm-dAK and potential drug design 
As bacteria increase their antibiotic resistance we need to develop new anti-
bacterial agents (Rice, 2006). Several pathogenic gram positive bacteria possess a 
dNK belonging to the dCK/dGK family, which could be potential targets for anti-
bacterial agents. In this study we investigated a mycoplasmic dNK, a dAK from 
Mm. In Uu, no genes corresponding to RNR have been found which render it   34 
 
 
dependent on the salvage enzymes and thus a good target for drug design (Glass, 
et al., 2000). With the structure of Mm-dAK, we have a model structure for future 
design of new anti-mycoplasmic agents. By structural comparison of Mm-dAKs 
with its human counterparts dCK and dGK, we have tried to reveal differences 
that can be exploited in the design of anti-bacterial agents. Modifications at the C2 
position of an adenine substrate would be of interest for agents against pathogenic 
mycoplasmas since they possess a Met instead of a Tyr and thus have more space 
around this position. A C2 modification could then interact with the conserved 
Asn in myoplasmas.        
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5. Human phosphoribosyltransferase domain 
containing 1, PRTFDC1 (Paper IV) 
5.1. Aim of study 
This study was carried out at the Structural Genomics Consortium (SGC) at 
Karolinska Insitutet, Stockholm. PRTFDC1 is a human enzyme of unknown 
function highly similar to the human hypoxanthine guanine 
phosphoribosyltransferase (HPRT). By structural determination and biochemical 
studies our aim was to elucidate the potential function of PRTFDC1.   
 
5.2. Background 
Recently, a homolog of HPRT, PRTFDC1, was investigated by bioinformatical 
approaches (Keebaugh, Sullivan & Thomas, 2006; Keebaugh, Sullivan & Thomas, 
2007; Nicklas, 2006). This gene has been classified as having an unknown 
function. As the name indicates it has a domain similar to 
phosphoribosyltransferases. PRTFDC1 are sequentially very similar to HPRT with 
a sequence identity of ~65%. Different HPRTs, both mammalian and bacterial, 
have high sequence similarities. Comparing human HPRT with a bacterial (E. coli) 
HPRT shows a sequence identity of ~29% and a similarity of ~44%. Among 
different HPRTs there are eleven invariant residues in proximity to the active site, 
with an exception for Giardia lamblia where only nine of these residues are 
conserved (Craig & Eakin, 2000). None of the PRTFDC1 sequences investigated 
by Keebaugh, et al. (2007) possessed all the invariant residues (Keebaugh, 
Sullivan & Thomas, 2007). In the human HPRT an aspartic acid at position 137 is 
believed to act as the catalytic acid/base and mutational studies of this residue to 
an asparagine showed a 30-fold reduction in catalytic efficiency (Canyuk, Focia & 
Eakin, 2001; Xu & Grubmeyer, 1998).  In Leishmania donovani adenine 
phosphoribosyltransferase (APRT) the corresponding residue is an alanine, 
indicating a different mechanism or a movement of a distant amino acid during 
catalysis (Craig & Eakin, 2000). Lys165 (HPRT numbering) is critical for 
discriminating substrates, since the NZ of the lysine is forming a hydrogen bond 
with the 6-oxo of the base. If this lysine is mutated to serine additional activity 
with adenine is obtained (Munagala, Chin & Wang, 1998).  
 
5.3. Structure of PRTFDC1 
Crystals of PRTFDC1 belonged to the space group P321 and had two subunits in 
the asymmetric unit. PRTFDC1 revealed a structure similar to other known 
HPRTs. Despite co-crystallization with PRPP, electron density corresponding to a 
GMP was found in the active site. This indicates that the GMP was obtained 
during expression. A similar result was observed for xanthine 
phosphoribosyltransferase from Bacillus subtilis (Arent et al., 2006). The structure 
of PRTFDC1 can be divided into two domains, a core and a hood domain. (Eads et 
al., 1994). The core domain consists of a six stranded twisted parallel β-sheet with 
the β-strands in the order 187634. Three α-helices surround the central β-sheet. β4 in the β-sheet is extended into a β-ribbon with β5 and this part of the structure is 
referred to as loop II. The hood domain is mainly built up by parts from the N- and 
C-terminus (Figure 12A). Using symmetry operations the two monomers in the 
asymmetric unit can generate a tetramer (Figure 13A).  
 
  A
B C
β1 β8
β7
β6
β3
β4
β5
β2
β9
α1
α2
α3
α4
Gly/Asp
Loop II
Figure 12. (A) Monomer of PRTFDC1 with GMP, a phosphate ion and two calcium ions 
bound. (B) Surface representation of PRTFDC1, GMP, calcium ions and the phosphate ion 
are colored in red. (C) Active site comparison of PRTFDC1 and HPRT (PDB-code: 1BZY) 
in brown and black respectively. GMP, a phosphate ion and two calcium ions from the 
PRTFDC1 structure are shown in brown. Loop II is shown with Cα-trace in both 
structures. Residues are shown with sticks and the Gly/Asp difference between HPRT and 
PRTFDC1 are shown.
Core
Hood
Loop II
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  36 
 
 5.3.1. Loop II 
This loop encloses the active site in several transition state analog structures, but is 
otherwise flexible and not observed (Focia, Craig & Eakin, 1998; Shi et al., 1999). 
Deletion of seven residues of loop II in Trypanosoma cruzi HPRT showed 
practically unchanged Km values for the substrates Hx and G while the catalytic 
efficiency decreased 240- to 1400-fold compared to the wild type. These results 
indicate that loop II is not directly involved in binding substrates but rather in 
catalysis (Lee et al., 2001). In PRTFDC1 this loop is clearly visible in one subunit, 
where the loop is formed as a long anti-parallel β-ribbon. The loop, however, does 
not cover the active site but stretches out from the protein forming interactions 
with a symmetry related molecule (Figure 13B). Two mutations in this region, 
S103R and S109L, lead to gout (Sculley et al., 1992).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AB
Figure 13. (A) tetramer generated from symmetry related molecules. (B), interactions of 
loop II with symmetry related molecules.  
5.3.2. Invariant residues 
Among eukaryotic HPRTs, eleven residues flanking the active site are invariant, 
while none of the compared PRTFDC1 sequences showed complete conservation. 
The most common substitution for PRTFDC1s were the Asp137 to Gly 
(Keebaugh, Sullivan & Thomas, 2007). A comparison of the human HPRT and 
PRTFDC1 shows nearly identical positions of these residues, with the exception 
of the Ser-Tyr couple which swings in to cover the active site in HPRT while it is 
pointing away in the PRTFDC1 leaving the active site very open (Figure 12B and 
C). By superposing the PRTFCD1 with other known HPRTs illustrates that the 
core structures are well conserved and the major differences between the 
structures are the flexible loop II.  
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5.3.3. Is PRTFDC1 an active enzyme? 
Since PRTFDC1 has a Gly substitution at the position for the believed catalytic 
residue it was proposed to have lost its phosphoribosyltransferase activity. The 
mouse PRTFDC1 was recently discovered to be inactive and hypothesized to be a 
cause for the development of the neurological symptoms of Lesch-Nyhan disease 
since HPRT deficient mice did not display these symptoms (Keebaugh, Sullivan & 
Thomas, 2007). To investigate the potential function of PRTFDC1, a basic 
spectrophotometric assay was utilized (Hill, 1970). The forward reaction showed 
activity using Hx and G together with PRPP with Hx as the preferred substrate. Hx 
as a favorable substrate also coincides with the performed thermofluor assay 
(Ericsson et al., 2006), where the highest increase in melting temperature was 
obtained using IMP. In the reverse reaction no detectable activity with IMP as a 
substrate was observed. The low or not detectable activities might be an effect of 
the pre bound GMP and insensitivity of the spectrophotometric assay.  
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6. Conclusions and future perspectives 
In this thesis structural studies of salvage enzymes in the nucleotide metabolism 
were investigated. Three new structures, human TK1, a mycoplasmic dAK, and 
the human HPRT homolog, PRTFDC1, were solved and investigated. In addition 
a structural study of a Dm-dNK mutant displaying changed behavior was carried 
out.  
 
6.1. Human TK1 
The human TK1 and a mycoplasmic TK were the first enzymes belonging to the 
TK1 family to be solved, and revealed a structure different from earlier known 
dNKs. Comparison of the human and bacterial TK showed high structural 
similarity between the enzymes. The TK structure is composed of two domains, an 
α/β domain similar to RecA-F1ATPase family and a second domain referred to as 
the lasso domain. The lasso domain closes down over the active site and is 
stabilized by a structural zinc coordinated by four cysteines. The structure 
provides an explanation for the narrow substrate specificity of TKs and will be a 
good starting point for the design of new NAs or potential inhibitors for the 
mycoplasmic enzyme. To study interactions between TK1 and NAs, further 
structural investigations are needed. How are NAs with modifications such as, 
3´OH of the deoxyribose and the N3 position of the thymine moieties bound to the 
protein?  
 
6.2. Dm-dNK N64D 
A double mutant N45D/N64D in Dm-dNK was found using a directed evolution 
study, and displayed an increased sensitivity towards AZT when transformed into 
a TK deficient E. coli strain. Furthermore the double mutant displayed a decreased 
inhibitory effect with the end product dTTP. Kinetic studies revealed that the 
N64D mutant was responsible for the changed behavior. Structural studies with a 
bound substrate revealed a destabilized LID region. The hydrogen bond between 
Asp64 and Glu171 was lost, leading to a flexible LID region, and a weaker 
binding of dT. The flexible LID region makes the substrate binding site slightly 
bigger which may give more space for the AZT molecule to bind. In the complex 
with the end product dTTP, Asp64 and Glu171 is still hydrogen bonded. This 
observation revealed that the decreased inhibition can be explained by the high 
energy cost of keeping these two carboxylates together. Modifying Dm-dNK into 
an enzyme displaying increased activity towards analogs while the activities of 
natural substrates are decreased is of interest in suicide gene/chemotherapy using 
the Dm-dNK gene. Can more mutations increase sensitivity and decrease activity 
towards natural substrates even further?? How is the Dm-dNK mutant behaving in 
vivo??  
 
6.3. Mm-dAK 
Mm-dAK represents the first bacterial dNK belonging to the dCK/dGK family. 
The Mm-dAK is structurally similar to its human counterparts dCK and dGK.   40 
 
 
Three complexes of the protein were obtained with two feedback inhibitors, dATP 
and dCTP, and two products, dCMP and dCDP. Mm-dAK prefers the substrates 
dA, dG, and dC, in order of catalytic efficiency. The crystal structure co-
crystallized with dCTP, which was supposed to work as a phosphate donor, was 
surprisingly bound as a feedback inhibitor. The Mm-dAK structures, compared 
with their human counterparts, revealed residues important for substrate 
specificity. Here we have combined structural and biochemical data to find 
potential leads for future development of new anti-bacterial agents towards 
different pathogenic mycoplasma. How does NAs bind to the protein?? How is dG 
bound to dNKs?? These are questions that are still unanswered and hopefully 
future studies will reveal these answers.    
 
6.4. PRTFDC1 
The human homolog of HPRT, PRTFDC1 was classified as having an unknown 
function, although it possessed a phosphoribosyltransferase domain. To elucidate 
the potential function of PRTFDC1 both structural and biochemical data were 
obtained. The structure revealed a bound GMP in the active site despite co-
crystallization using PRPP. A spectrophotometric assay displayed some activity 
using the substrate Hx and G in the forward assay while no activity was observed 
for the reverse reaction IMP. A thorough kinetic investigation, using more 
sensitive assays is needed to reveal the substrate specificity and the activity of 
PRTFDC1, for a precise comparison of HPRT. There are still many unanswered 
questions concerning the biological role of PRTFDC1. Among those that need to 
be answered are: Is the activity of PRTFDC1 enough for compensation of an 
inactive or partially active HPRT? Does PRTFDC1 have any connection to the 
Lesch-Nyhan disease?  
 
These questions are beyond the scope of this thesis though the experiments we 
describe here are a necessary foundation to finding solutions to these important 
issues. 
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